Skip to main content
INDV
NASDAQ Life Sciences

Oaktree Exits 5%+ Stake in Indivior, Sells 6.5M Shares

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$38.1
Mkt Cap
$4.51B
52W Low
$22.22
52W High
$42.81
52W Position info
71% above low
Off High info
11% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

INDV sits 71% above its 52-week low of $22.22.

Summary

Oaktree Capital's funds have exited their 5%+ common stock position in Indivior, selling 6.48 million shares between June 26 and August 12, 2026, and now hold only convertible notes representing 0.76% of the company.


Key Events · Ownership and Investor Activity · INDV

  • Oaktree Exits 5%+ Stake

    Oaktree funds ceased to be beneficial owners of more than 5% of Indivior common stock on or prior to August 10, 2026, triggering this exit filing.

  • 6.48M Shares Sold

    Between June 26 and August 12, 2026, Oaktree sold 6,477,212 shares at prices ranging from $37.75 to $42.13, with the largest single sale of 4.54 million shares on August 12.

  • Convertible Notes Remain

    Oaktree still holds $37.872 million principal amount of 0.625% Convertible Senior Notes due 2031, convertible into 909,053 shares (0.76% of outstanding).

  • Timing Coincides with Merger

    The exit comes just days after Indivior announced an all-stock merger of equals with Supernus Pharmaceuticals on August 3, 2026.


Analysis · INDV · Life Sciences

Oaktree Capital's funds have sold down their entire common stock position in Indivior, dropping below the 5% reporting threshold. The sales occurred between June 26 and August 12, 2026, at prices ranging from $37.75 to $42.13, totaling approximately 6.48 million shares. This is a significant exit by a major institutional holder, coming just days after Indivior announced a merger of equals with Supernus Pharmaceuticals. The timing suggests Oaktree may be reducing exposure ahead of the merger or taking profits after a strong run in the stock. The remaining position is now only in convertible notes, representing less than 1% of the company.

How filings like this one have moved

In the 30 days to Nov 4, 2026, 41.4% of the 1217 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.35%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, INDV was trading at $38.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.5B. The 52-week trading range was $22.22 to $42.81. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

INDV - Latest Insights

INDV
Nov 02, 2026, 9:27 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $35.56
Real-time Price: $36.41 info
Change: +$0.850 (+2%) info
Market Cap: $4.282B info
INDV
Oct 29, 2026, 4:09 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $35.25
Real-time Price: $36.41 info
Change: +$1.16 (+3%) info
Market Cap: $4.282B info
INDV
Oct 29, 2026, 8:14 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $36.51
Real-time Price: $36.41 info
Change: -$0.100 (-0.27%) info
Market Cap: $4.282B info
INDV
Oct 29, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $34.44
Real-time Price: $36.41 info
Change: +$1.97 (+6%) info
Market Cap: $4.282B info
INDV
Oct 29, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $34.44
Real-time Price: $36.41 info
Change: +$1.97 (+6%) info
Market Cap: $4.282B info